ERBB2 and lung adenocarcinoma: There are a number of other important recognized oncogenic alterations in lung adenocarcinoma that may be also used as potentially targetable alterations, including B-Raf proto-oncogene (BRAF), Erb-B2 Receptor Tyrosine Kinase 2 (ERBB2), mesenchymal-epithelial transition factor (MET), and rearranged during transfection (RET).